Norgine Expands Medicines Manufacturing in Wales with £50M Investment

Norgine, a leading European specialty pharmaceutical company, has announced a new £23 million investment in its Hengoed, Wales manufacturing site, bringing the total investment at the facility to more than £50 million since 2022. According to the press release from Norgine, the investment will support the expansion of the company's medicines manufacturing capabilities in Wales. The project is supported by the Welsh Government and is part of Norgine's broader strategy to enhance its production capacity and supply chain resilience across Europe. 'This significant investment in our Hengoed site demonstrates our continued commitment to Wales and to ensuring we have the capabilities to meet the growing demand for our important medicines,' said Peter Stein, CEO of Norgine. 'The support of the Welsh Government has been instrumental in enabling us to expand our manufacturing footprint in the region.' The Hengoed facility currently produces a range of Norgine's specialty and generic medicines for distribution across Europe and other global markets. The new investment will allow the company to increase production volumes and introduce new manufacturing technologies to improve efficiency and sustainability. 'We are delighted that Norgine has chosen to further invest in its operations in Wales,' said Vaughan Gething, the Welsh Government's Minister for the Economy. 'This is a clear vote of confidence in the skilled workforce and supportive business environment that Wales can offer global life sciences companies.' The news comes as pharmaceutical companies worldwide are seeking to bolster their manufacturing capabilities and supply chain resilience in the wake of the COVID-19 pandemic. Norgine's investment in Wales underscores the continued importance of Europe as a hub for medicines production and distribution.